Drug Profile
MEDI 6012
Alternative Names: ACP-501; MEDI-6012; recombinant-lecithin-cholesterol-acyltransferase; rhLCAT - AstraZenecaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AlphaCore Pharma
- Developer AstraZeneca; MedImmune
- Class Acyltransferases; Antianaemics; Cardiovascular therapies; Enzymes; Recombinant proteins
- Mechanism of Action Apolipoprotein A I stimulants; Cholesterol modulators; Transferase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes; Adrenal gland disorders; Anaemia; Arterial thrombosis; Atherosclerosis; Coronary artery disease; Lecithin acyltransferase deficiency; Myocardial infarction; Sickle cell anaemia
Most Recent Events
- 01 Apr 2021 Discontinued - Phase-I for Arterial thrombosis in USA (IV) (AstraZeneca pipeline, May 2021)
- 01 Apr 2021 Discontinued - Phase-II for Acute coronary syndromes in USA (IV) (AstraZeneca pipeline, May 2021)
- 01 Apr 2021 Discontinued - Phase-II for Atherosclerosis in USA (IV) (AstraZeneca pipeline, May 2021)